Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common shares
-
Shares outstanding
-
250M
-
Number of holders
-
118
-
Total 13F shares, excl. options
-
107M
-
Shares change
-
+12.1M
-
Total reported value, excl. options
-
$53.8M
-
Value change
-
+$3.89M
-
Put/Call ratio
-
0
-
Number of buys
-
55
-
Number of sells
-
-28
-
Price
-
$0.50
Significant Holders of Lineage Cell Therapeutics, Inc. - Common shares (LCTX) as of Q4 2024
135 filings reported holding LCTX - Lineage Cell Therapeutics, Inc. - Common shares as of Q4 2024.
Lineage Cell Therapeutics, Inc. - Common shares (LCTX) has 118 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 107M shares
of 250M outstanding shares and own 42.75% of the company stock.
Largest 10 shareholders include BROADWOOD CAPITAL INC (41.7M shares), BlackRock, Inc. (10.1M shares), VANGUARD GROUP INC (8.63M shares), PERCEPTIVE ADVISORS LLC (7.24M shares), Defender Capital, LLC. (5.96M shares), RAFFLES ASSOCIATES LP (5.49M shares), Alyeska Investment Group, L.P. (3.95M shares), GEODE CAPITAL MANAGEMENT, LLC (3.69M shares), STATE STREET CORP (2.67M shares), and DAFNA Capital Management LLC (2.51M shares).
This table shows the top 118 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.